Clinical Psychopharmacology and Neuroscience
September 16, 2026
Shih‐Hsien Lin, Muhammad Abdullah, Huai‐Hsuan Tseng et al.
Objective: Mindfulness is an effective non-pharmacological intervention for mental health.However, little is known about the underlying neurological mechanisms involved, especially glutamate, -aminobutyric acid (GABA), and the excitation-inhibition (E-I) balance.This study examined changes in these markers after mindfulness training and whether these changes are related to the baseline...
Clinical Psychopharmacology and Neuroscience
July 31, 2026
Won-Seok Choi, Moon‐Soo Lee, Mi Kyoung Seo et al.
Major depressive disorder remains a leading cause of global disability, and many patients show limited response to conventional antidepressants.Increasing evidence suggests that a substantial subgroup exhibits chronic low-grade inflammation, which may constrain synaptic plasticity and contribute to persistent depressive symptoms.In this review, we propose that depression can be conceptualized...
Clinical Psychopharmacology and Neuroscience
July 14, 2026
Alessandro Serretti
The introduction of ketamine and its S-enantiomer, esketamine, has been one of the most consequential advances in treatment-resistant depression (TRD) in recent decades, demonstrating that rapid and clinically meaningful antidepressant effects can occur within hours, even in patients who have not responded to conventional treatments.However, this advance has not resolved the clinical problem of...
Clinical Psychopharmacology and Neuroscience
May 21, 2024
S Morris
5 citations
Psilocybin is gaining popularity as research shows potential benefits to those with anxiety, depression, and other mental health conditions. Individuals with risk factors for psychosis are typically excluded from such studies, limiting the empiric research of the risks and benefits in vulnerable populations. In the real-world setting, many individuals who seek treatment with psilocybin will...
Clinical Psychopharmacology and Neuroscience
November 30, 2023
Sunghwan Kim, Won-Seok Choi, Hyun Kook Lim et al.
16 citations
Previous studies suggested effectiveness of psilocybin in the field of mental health. FDA designated psilocybin as a "breakthrough therapy" for the treatment of treatment-resistant depression (TRD) in 2018. This paper provided a review of psilocybin's potential role in treatment of depression by focusing on published clinical trials. Studies showed that psilocybin, an agonist on 5-HT2A...
Clinical Psychopharmacology and Neuroscience
October 16, 2023
Tessa Watford, Naqash Masood
21 citations
Psilocybin is a classical psychedelic which has been utilised for healing purposes for millenia. However, with its classification as a Schedule I substance, research into this compound is scarce with few FDA-approved clinical studies. Despite this, profound findings into its antidepressant effects (largely through its action on 5-HT1a receptors) in mental illnesses such as major depressive...
Clinical Psychopharmacology and Neuroscience
July 17, 2023
B. McCarthy, Hannah Bunn, Morgan Santalucia et al.
Depression is a significant cause of morbidity and mortality globally. Although various pharmacologic options exist for depression, treatments are limited by delayed or incomplete therapeutic response, low rates of remission, and adverse effects necessitating effective, fast-acting, and better tolerated alternatives. The purpose of this review is to describe the safety and efficacy of...
Clinical Psychopharmacology and Neuroscience
April 1, 2015
Chun Yang, Kenji Hashimoto
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Combination of Nitrous Oxide with Isoflurane or Scopolamine for Treatment-resistant Major...
Clinical Psychopharmacology and Neuroscience
December 26, 2014
Georg Northoff
65 citations
While several hypotheses about the neural mechanisms underlying auditory verbal hallucinations (AVH) have been suggested, the exact role of the recently highlighted intrinsic resting state activity of the brain remains unclear. Based on recent findings, we therefore developed what we call the 'resting state hypotheses' of AVH. Our hypothesis suggest that AVH may be traced back to abnormally...
Clinical Psychopharmacology and Neuroscience
December 1, 2012
N. Volf, G. Hu, Ming Li
Objective Iptakalim is a putative ATP-sensitive potassium (KATP) channel opener. It is also a novel nicotinic acetylcholine receptor (nAChR) blocker and can antagonize nicotine-induced increase in dopamine release in the nucleus accumbens. Our recent work also shows that iptakalim exhibits a clozapine-like atypical antipsychotic profile, indicating that iptakalim may possess a dual action...